tiprankstipranks
Trending News
More News >

Vanda Pharmaceuticals says Bysanti NDA decision expected in early 2026

Vanda Pharmaceuticals (VNDA) announced that the U.S. FDA informed Vanda that the New Drug Application for Bysanti has been filed, and that at this time no potential review issues have been identified. The FDA has set February 21, 2026 as the target date for decision on this application.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1